Notably, tirzepatide (Zepbound) was not approved for weight management in patients with overweight or obesity until shortly before the patient-identification window closed, resulting in most patients in the tirzepatide cohort receiving Mounjaro, which was assumed to be used off-label for chronic weight management in the absence of T2DM
By week 12, clinical trial participants achieved an average of 8.7% body weight reduction across all dose groups
Pricing in the online semaglutide space can be structured in several ways, and the differences aren't always immediately obvious
Cardinal Health reports sales boost from GLP-1 medications GLP-1 prescriptions grew more than 2,000% from 2019 to 2022
Two structural modifications (C18 fatty acid chain enabling albumin binding, and a substitution at position 8 conferring DPP-4 resistance) extend its half-life to approximately 1 week, enabling once-weekly subcutaneous dosing